These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36511813)

  • 1. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
    Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB; Radzievski R; Ellis ML; Manning KE; Wali B; Valanparambil RM; Maples KT; Baymon E; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S; Roback JD; Sette A; Ahmed R; Suthar MS; Neish AS; Dhodapkar MV; Dhodapkar KM
    Blood Cancer Discov; 2023 Mar; 4(2):106-117. PubMed ID: 36511813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.
    Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S
    Front Immunol; 2022; 13():1039163. PubMed ID: 36505453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
    López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
    Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
    Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S; Azeem M; Manalo J; Switchenko JM; Chang A; Linderman SL; Roback JD; Dhodapkar KM; Ahmed R; Suthar MS; Neish AS; Dhodapkar MV
    J Clin Oncol; 2022 Sep; 40(26):3057-3064. PubMed ID: 35259002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study.
    Ferreira VH; Ierullo M; Mavandadnejad F; Kurtesi A; Hu Q; Hardy WR; Hall VG; Pinzon N; Yotis D; Gingras AC; Belga S; Shalhoub S; Hébert MJ; Humar A; Kabbani D; Kumar D
    Clin Infect Dis; 2023 Jul; 77(2):229-236. PubMed ID: 36975097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.
    Zitvogel L; Derosa L; Kroemer G
    Blood Cancer Discov; 2023 May; 4(3):172-175. PubMed ID: 37078891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis.
    Maglione A; Francese R; Arduino I; Rosso R; Matta M; Rolla S; Lembo D; Clerico M
    Front Immunol; 2023; 14():1205879. PubMed ID: 37409134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.
    Zhu L; Mao N; Yi C; Simayi A; Feng J; Feng Y; He M; Ding S; Wang Y; Wang Y; Wei M; Hong J; Li C; Tian H; Zhou L; Peng J; Zhang S; Song C; Jin H; Zhu F; Xu W; Zhao J; Bao C
    Emerg Microbes Infect; 2023 Dec; 12(1):2146535. PubMed ID: 36373485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV.
    Casado JL; Vizcarra P; Martín-Colmenarejo S; Del Pino J; Gomez-Maldonado S; Martín-Hondarza A; Vallejo A
    AIDS; 2023 May; 37(6):877-882. PubMed ID: 36779501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.
    Werbel WA; Karaba AH; Chiang TP; Massie AB; Brown DM; Watson N; Chahoud M; Thompson EA; Johnson AC; Avery RK; Cochran WV; Warren D; Liang T; Fribourg M; Huerta C; Samaha H; Klein SL; Bettinotti MP; Clarke WA; Sitaras I; Rouphael N; Cox AL; Bailey JR; Pekosz A; Tobian AAR; Durand CM; Bridges ND; Larsen CP; Heeger PS; Segev DL;
    Am J Transplant; 2023 Jun; 23(6):744-758. PubMed ID: 36966905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
    Chen Y; Yin S; Tong X; Tao Y; Ni J; Pan J; Li M; Wan Y; Mao M; Xiong Y; Yan X; Yang Y; Huang R; Wu C; Shen H
    Clin Microbiol Infect; 2022 Mar; 28(3):410-418. PubMed ID: 34715346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.